You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a novel highly effective influenza vaccine

    SBC: Flugen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Rabbit InMAD Discovery of Novel Biomarkers for POC Tuberculosis Diagnostic Assay

    SBC: Immuno-mycologics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB is a chronic infectious disease that infects approximately one third of the worldandapos s population Eighty five percent of the estimated million new cases of TB in occurred in resource limited countries located in Asia and Africa In there were million deaths from TB among HIV negative patients and additional TB d ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a Nrf2 activator for the treatment of scleroderma

    SBC: CUREVEDA, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells

    SBC: IMMUVEN, INC.            Topic: NCI

    Project Summary The goal of this STTR grant application is to engineer powerful NK cell-based cytolytic effector cells for therapeutic applications. The cells will combine the selectivity and specificity of T cells and the ability of NK cells to mediate effective cytolytic activity against a wide spectrum of aberrant cells, including those with impaired adhesion properties. To achieve this goal we ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government